search
Back to results

An Open-Label Study of Oral NNZ-2591 in Pitt Hopkins Syndrome (PTHS-001) (PTHS-001)

Primary Purpose

Pitt Hopkins Syndrome

Status
Recruiting
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
NNZ-2591
Sponsored by
Neuren Pharmaceuticals Limited
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pitt Hopkins Syndrome focused on measuring Pitt Hopkins Syndrome

Eligibility Criteria

3 Years - 17 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Clinical diagnosis of PTHS with a documented disease-causing genetic etiology for the disorder.
  2. Males or females aged 3-17 years.
  3. Body weight of 12kg or higher at screening
  4. Subjects with a Clinical Global Impression- Severity (CGI-S) score of 4 or greater at the Screening visit.
  5. Not actively undergoing regression or loss of skills, defined as no persistent loss of previously acquired developmental skills for a period within 3 months of the Screening visit
  6. Each subject must be able to swallow the study medication provided as a liquid solution.
  7. Caregiver(s) must have sufficient English language skills.

Exclusion Criteria:

  1. Body weight <12kg at screening
  2. Clinically significant abnormalities in safety laboratory tests and vital signs at Screening.
  3. Abnormal QTcF interval or prolongation at Screening.
  4. Any other clinically significant finding on ECG at the Screening visit.
  5. Positive for severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) and previous COVID 19 infection with last 12 months that required hospitalization.
  6. Unstable or changes Psychotropic treatment 2 weeks prior to screening
  7. Excluded concomitant treatments.
  8. Actively undergoing regression or loss of skills.
  9. Unstable seizure profile.
  10. Current clinically significant renal conditions and abnormalities
  11. Current clinically significant cardiovascular, hepatic, gastrointestinal, respiratory, endocrine disease, or clinically significant organ impairment.
  12. Current clinically significant hypo- or hyperthyroidism, Type 1 or Type 2 diabetes mellitus requiring insulin (whether well controlled or uncontrolled), or uncontrolled Type 1 or Type 2 diabetes.
  13. Has planned surgery during the study.
  14. History of, or current, cerebrovascular disease or brain trauma.
  15. History of, or current catatonia or catatonia-like symptoms.
  16. History of, or current, malignancy.
  17. Current major or persistent depressive disorder (including bipolar depression).
  18. Significant, uncorrected visual or uncorrected hearing impairment.
  19. Allergy to strawberry.
  20. Positive pregnancy test
  21. Subject is judged by the Investigator or Medical Monitor to be inappropriate for the study

Sites / Locations

  • University of Alabama at BirminghamRecruiting
  • University of California at San FranciscoRecruiting
  • Children's Hospital ColoradoRecruiting
  • Rush University Medical CenterRecruiting
  • UT SouthwesternRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

NNZ-2591

Arm Description

NNZ-2591 oral solution (50mg/mL) to be administered twice daily dose for 13 weeks.

Outcomes

Primary Outcome Measures

Safety and Tolerability
To examine the incidence, severity and frequency of adverse events (AEs), including serious adverse events (SAEs) during treatment with NNZ-2591.
Pharmacokinetic - Measurement of Cmax
Maximum observed concentration (Cmax) of NNZ-2591
Pharmacokinetic - Measurement of AUC
Area under the concentration-time curve of NNZ-2591
Pharmacokinetic - Measurement of time to Cmax
Time to Cmax of NNZ-2591
Pharmacokinetic - Measurement of t1/2
Apparent terminal elimination half-life of NNZ-2591

Secondary Outcome Measures

Exploratory efficacy measurement
Assessed by Pitt Hopkins syndrome-specific Clinical Global Impression Scale-Overall Improvement (CGI-I)
Exploratory efficacy measurement
Assessed by Caregiver Impression of Improvement
Exploratory efficacy measurement
Assessed by Pitt Hopkins syndrome-specific Clinical Global Impression Scales-Domain Improvement
Exploratory efficacy measurement
Assessed by Pitt Hopkins syndrome-specific Clinical Global Impression Scale-Severity (CGI-S)-Overall and Domain
Exploratory efficacy measurement
Assessed by Caregiver Top 3 Concerns Likert Scale
Exploratory efficacy measurement
Assessed by MacArthur-Bates Communicative Development Inventory (MB-CDI)
Exploratory efficacy measurement
Assessed by Observer-Reported Communication Ability (ORCA)
Exploratory efficacy measurement
Assessed by Aberrant Behavior Checklist-2 (ABC-2)
Exploratory efficacy measurement
Assessed by Child Sleep Habits Questionnaire (CSHQ)
Exploratory efficacy measurement
Assessed by Gastrointestinal Health Questionnaire (GIHQ)
Exploratory efficacy measurement
Assessed by Vineland Adaptive Behavior Scales-3, Interview version
Exploratory efficacy measurement
Assessed by Modified two-minute walk test
Exploratory efficacy measurement
Assessed by Bayley Scales of Infant Development 4 (BSID 4) motor scale
Exploratory efficacy measurement
Caregiver Diaries
Exploratory efficacy measurement
Assessed by Quality of Life Inventory-Disability (QI-Disability)
Exploratory efficacy measurement
Assessed by Impact of Childhood Neurological Disability (ICND)-Overall quality of life rating

Full Information

First Posted
August 24, 2021
Last Updated
August 3, 2023
Sponsor
Neuren Pharmaceuticals Limited
search

1. Study Identification

Unique Protocol Identification Number
NCT05025332
Brief Title
An Open-Label Study of Oral NNZ-2591 in Pitt Hopkins Syndrome (PTHS-001)
Acronym
PTHS-001
Official Title
An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Pitt Hopkins Syndrome (PTHS-001)
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 14, 2022 (Actual)
Primary Completion Date
April 30, 2024 (Anticipated)
Study Completion Date
April 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Neuren Pharmaceuticals Limited

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
A study of the safety, tolerability and pharmacokinetics of NNZ-2591 and measures of efficacy in children and adolescents with Pitt Hopkins Syndrome.
Detailed Description
The primary purpose of this study is to investigate the safety, tolerability and pharmacokinetics of treatment with NNZ-2591 oral solution in children and adolescents with Pitt Hopkins Syndrome. The secondary purpose is to investigate measures of efficacy. Subjects will receive treatment with NNZ-2591 oral solution (50 mg/mL) doses for a total of 13 weeks.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pitt Hopkins Syndrome
Keywords
Pitt Hopkins Syndrome

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
NNZ-2591
Arm Type
Experimental
Arm Description
NNZ-2591 oral solution (50mg/mL) to be administered twice daily dose for 13 weeks.
Intervention Type
Drug
Intervention Name(s)
NNZ-2591
Other Intervention Name(s)
Cyclo-L-Glycyl-L-2-Allylproline
Intervention Description
NNZ-2591 oral solution (50mg/mL) to be administered twice daily dose for 13 weeks.
Primary Outcome Measure Information:
Title
Safety and Tolerability
Description
To examine the incidence, severity and frequency of adverse events (AEs), including serious adverse events (SAEs) during treatment with NNZ-2591.
Time Frame
13 weeks
Title
Pharmacokinetic - Measurement of Cmax
Description
Maximum observed concentration (Cmax) of NNZ-2591
Time Frame
13 weeks
Title
Pharmacokinetic - Measurement of AUC
Description
Area under the concentration-time curve of NNZ-2591
Time Frame
13 weeks
Title
Pharmacokinetic - Measurement of time to Cmax
Description
Time to Cmax of NNZ-2591
Time Frame
13 weeks
Title
Pharmacokinetic - Measurement of t1/2
Description
Apparent terminal elimination half-life of NNZ-2591
Time Frame
13 weeks
Secondary Outcome Measure Information:
Title
Exploratory efficacy measurement
Description
Assessed by Pitt Hopkins syndrome-specific Clinical Global Impression Scale-Overall Improvement (CGI-I)
Time Frame
13 weeks
Title
Exploratory efficacy measurement
Description
Assessed by Caregiver Impression of Improvement
Time Frame
13 weeks
Title
Exploratory efficacy measurement
Description
Assessed by Pitt Hopkins syndrome-specific Clinical Global Impression Scales-Domain Improvement
Time Frame
13 weeks
Title
Exploratory efficacy measurement
Description
Assessed by Pitt Hopkins syndrome-specific Clinical Global Impression Scale-Severity (CGI-S)-Overall and Domain
Time Frame
13 weeks
Title
Exploratory efficacy measurement
Description
Assessed by Caregiver Top 3 Concerns Likert Scale
Time Frame
13 weeks
Title
Exploratory efficacy measurement
Description
Assessed by MacArthur-Bates Communicative Development Inventory (MB-CDI)
Time Frame
13 weeks
Title
Exploratory efficacy measurement
Description
Assessed by Observer-Reported Communication Ability (ORCA)
Time Frame
13 weeks
Title
Exploratory efficacy measurement
Description
Assessed by Aberrant Behavior Checklist-2 (ABC-2)
Time Frame
13 weeks
Title
Exploratory efficacy measurement
Description
Assessed by Child Sleep Habits Questionnaire (CSHQ)
Time Frame
13 weeks
Title
Exploratory efficacy measurement
Description
Assessed by Gastrointestinal Health Questionnaire (GIHQ)
Time Frame
13 weeks
Title
Exploratory efficacy measurement
Description
Assessed by Vineland Adaptive Behavior Scales-3, Interview version
Time Frame
13 weeks
Title
Exploratory efficacy measurement
Description
Assessed by Modified two-minute walk test
Time Frame
13 weeks
Title
Exploratory efficacy measurement
Description
Assessed by Bayley Scales of Infant Development 4 (BSID 4) motor scale
Time Frame
13 weeks
Title
Exploratory efficacy measurement
Description
Caregiver Diaries
Time Frame
13 weeks
Title
Exploratory efficacy measurement
Description
Assessed by Quality of Life Inventory-Disability (QI-Disability)
Time Frame
13 weeks
Title
Exploratory efficacy measurement
Description
Assessed by Impact of Childhood Neurological Disability (ICND)-Overall quality of life rating
Time Frame
13 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
3 Years
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Clinical diagnosis of PTHS with a documented disease-causing genetic etiology for the disorder. Males or females aged 3-17 years. Body weight of 12kg or higher at screening Subjects with a Clinical Global Impression- Severity (CGI-S) score of 4 or greater at the Screening visit. Not actively undergoing regression or loss of skills, defined as no persistent loss of previously acquired developmental skills for a period within 3 months of the Screening visit Each subject must be able to swallow the study medication provided as a liquid solution. Caregiver(s) must have sufficient English language skills. Exclusion Criteria: Body weight <12kg at screening Clinically significant abnormalities in safety laboratory tests and vital signs at Screening. Abnormal QTcF interval or prolongation at Screening. Any other clinically significant finding on ECG at the Screening visit. Positive for severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) and previous COVID 19 infection with last 12 months that required hospitalization. Unstable or changes Psychotropic treatment 2 weeks prior to screening Excluded concomitant treatments. Actively undergoing regression or loss of skills. Unstable seizure profile. Current clinically significant renal conditions and abnormalities Current clinically significant cardiovascular, hepatic, gastrointestinal, respiratory, endocrine disease, or clinically significant organ impairment. Current clinically significant hypo- or hyperthyroidism, Type 1 or Type 2 diabetes mellitus requiring insulin (whether well controlled or uncontrolled), or uncontrolled Type 1 or Type 2 diabetes. Has planned surgery during the study. History of, or current, cerebrovascular disease or brain trauma. History of, or current catatonia or catatonia-like symptoms. History of, or current, malignancy. Current major or persistent depressive disorder (including bipolar depression). Significant, uncorrected visual or uncorrected hearing impairment. Allergy to strawberry. Positive pregnancy test Subject is judged by the Investigator or Medical Monitor to be inappropriate for the study
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
James Shaw
Phone
+61 427 299 669
Email
jshaw@neurenpharma.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
James Shaw
Organizational Affiliation
Neuren Pharmaceuticals
Official's Role
Study Director
Facility Information:
Facility Name
University of Alabama at Birmingham
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35294
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Cassandra Newsom
Phone
205-934-2352
Email
Cassandranewsom@uabmc.edu
Facility Name
University of California at San Francisco
City
San Francisco
State/Province
California
ZIP/Postal Code
94143
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alison Walmsley
Phone
408-334-5630
Email
alison.walmsley@ucsf.edu
Facility Name
Children's Hospital Colorado
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Eliana Obando
Phone
720-777-5378
Email
eliana.obando@childrenscolorado.org
Facility Name
Rush University Medical Center
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60612
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alison Bauman
Phone
312-942-2005
Email
Allison_L_Baumann@rush.edu
Facility Name
UT Southwestern
City
Dallas
State/Province
Texas
ZIP/Postal Code
75390
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jessica Clark
Phone
972-655-4847
Email
Jessica.Clark@UTSouthwestern.edu

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

An Open-Label Study of Oral NNZ-2591 in Pitt Hopkins Syndrome (PTHS-001)

We'll reach out to this number within 24 hrs